TherapeuticsMD, Inc.
TXMDNasdaq
$2.06
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↑ +79.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$23,978.40
Enterprise Value
$23,978.40
P/E
103.0
P/S
0.0
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$3.4M
Net Income (TTM)
$179,000.00
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-114.3%
Net Margin
5.3%
ROE
0.7%
ROIC
-11.2%
Debt / Equity
—
Net Cash
—
Return 1Y
+79.1%
Company profile
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone. It also manufactures and distributes branded and generic prescription prenatal vitamins.
- CEO
- Mark A. Glickman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 420
- Headquarters
- Florida
- Website
- therapeuticsmd.com
Earnings
TXMD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$724,000.00↑ +84.2%
Diluted EPS$0.01↓ -116.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $64.9M | $2.6M | $70.0M | $1.3M | $1.8M | $3.0M |
| Gross profit | $48.9M | $1.2M | $68.6M | $1.3M | — | — |
| Operating income | -$155.5M | -$79.6M | $1.2M | -$8.5M | -$6.1M | -$4.4M |
| Net income | -$183.5M | -$172.4M | $112.0M | -$10.3M | -$2.2M | -$569,000.00 |
| Diluted EPS | — | -$21.66 | $11.96 | -$0.99 | -$0.19 | -$0.05 |
| Operating cash flow | -$159.5M | -$142.7M | — | — | — | — |
| Free cash flow | -$159.7M | -$142.7M | — | — | — | — |
| Gross margin | 75.4% | 45.5% | 98.0% | 100.0% | — | — |
| Operating margin | -239.8% | -3092.8% | 1.7% | -654.6% | -347.1% | -145.3% |
| Net margin | -282.9% | -6700.9% | 160.1% | -789.4% | -123.9% | -18.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $234,000.00 | $547,000.00 | $667,000.00 | $393,000.00 | $952,000.00 | $784,000.00 | $893,000.00 | $724,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.8M | -$1.1M | -$1.0M | -$1.3M | -$695,000.00 | -$862,000.00 | -$1.6M | -$723,000.00 |
| Net income | -$1.1M | -$609,000.00 | $252,000.00 | -$653,000.00 | $551,000.00 | $152,000.00 | -$619,000.00 | $95,000.00 |
| Diluted EPS | -$0.09 | -$0.05 | $0.01 | -$0.06 | $0.05 | $0.01 | -$0.05 | $0.01 |
| Operating cash flow | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1191.9% | -207.3% | -157.0% | -326.0% | -73.0% | -109.9% | -173.8% | -99.9% |
| Net margin | -465.8% | -111.3% | 37.8% | -166.2% | 57.9% | 19.4% | -69.3% | 13.1% |
Company news
Nov 12, 2025
Aug 12, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-23 | Thompson Tommy G | Buy | 8,400 | $1.67 | $14,030.52 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.